Pressmeet Presentation Q2FY15

7/21/2019 Pressmeet Presentation Q2FY15

http://slidepdf.com/reader/full/pressmeet-presentation-q2fy15 1/13

©2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.

Q2 FY15PRESS MEET

Dr. Reddy’s Laboratories Limited

Oct 29, 2014




Q2 FY15 PRESS MEET

Business Highlights

2YoY growth rate

Gross Profit

EBIDTA

58.0%

8%58.5%

950

872

3,357

7%3,588

Revenues

R&D

30137%

411 8%

28.3%

24.3%9.0%

11.5%

% of revenues Q2FY15Q2FY14

₹ Crs

₹ Crs

₹ Crs




Q2 FY15 PRESS MEET

Business Highlights

US

1

India

2

Russia

& CIS

2

Europe

2

RoW

2

Country wise launches

2 3

3




Q2 FY15 PRESS MEET

Global Generics: ₹ 2,887 Cr (9% YoYGr)

4

US₹ 1,429 Cr (8%)

Emerging Markets₹ 834 Cr (14%)

India₹ 480 Cr (14%)

Europe₹ 143 Cr (-19%)




Q2 FY15 PRESS MEET

220Cumulative

ANDAs

72 Pendingfinal

approvals 45 Para IVs

11 First-to-Files (FTFs)

Global Generics: USMarket Share – Key Products

ANDA Pipeline

₹ CrRevenues

Product May Aug

Decitabine 62% 70%

Azacitidine 44% 54%

Zoledronic acid(5mg/100ml)

62% 56%

Ziprasidone 30% 48%

Metoprolol 19% 23%

Divalproex ER 11% 20%

Source: IMS total market share

Q2 FY 14 Q2 FY 15

1,324 1,429

8%

5




Q2 FY15 PRESS MEET

6

Global Generics: Emerging markets

₹ Cr Revenues

RUSSIA• YoY decline is primarily on account of

the devaluation of Rouble.

• IMS YTD Aug: Growth faster than themarket, both in unit and value terms

• IMS OTC YTD Aug: 4th fastestgrowing OTC company in Top 25(volume wise) with a growth rate of14% against a market growth of 1.4%

• OTC revenues at 34% to sales

RoW

• Venezuela: Revenues grew by 248% YoYin constant currency (103% unit growthagainst market growth of 1.3%)

Q2 FY 14 Q2 FY 15

465 413

269 421

Russia CIS & RoW

14%


http://slidepdf.com/reader/full/pressmeet-presentation-q2fy15 7/13©2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.

Q2 FY15 PRESS MEET

Q2 FY 14 Q2 FY 15

421 480

7

Global Generics: India

₹ Cr Revenues • Highest ever quarterly revenue.

• Healthy volume expansion in ourfocus brands

• 2 new products launched during thequarter

•

IMS MQT Aug 2014 growth of 8.8% vsIPM growth of 10.1%

14%

Key Product launches



Q2 FY15 PRESS MEET

8

PSAI

• API: Stability in revenue with bettermargin profile and higherdevelopmental sales

• CPS: Improving performance

• 3 US DMF filings during the quarter

₹ Cr

Q2 FY 14 Q2 FY 15

640 639 DMFs Pipeline

US 215

Europe 184

RoW 304

Cumulative 703

Revenues



Q2 FY15 PRESS MEET

9

CAPEX, R&D & Free cash-flows

Net Debt/Equity ratio

(Sep 2014)

0.10

% of revenues

591

767

1,240

388 411

FY 12 FY 13 FY 14 Q1 FY15 Q2 FY15

R&D ₹ Cr

6.1%6.6%

9.4%

11.0% 11.5%

695589

873

228 201

FY 12 FY 13 FY 14 Q1 FY15 Q2 FY15

Free cash flow ₹ Cr

686 667

1,008

217 233

FY 12 FY 13 FY 14 Q1 FY15 Q2 FY15

CAPEX ₹ Cr



Q2 FY15 PRESS MEET

Q&A Session

Q FY



Q2 FY15 PRESS MEET

11

P&L – Q2 FY 15₹ Cr

Particulars Q2 FY15 Q2 FY14 Gr%

Revenues 3,588 3,357 7%

Gross Profit 2,099 1,947 8%

% to revenues 58.5%

58.0%

SG&A 1,067 974 10%% to revenues 29.7% 29.0%

R&D 411 301 37%

% to revenues 11.5% 9%

EBITDA 872 950 -8.3%

% to revenues 24.3%

28.3%

PAT 574 690 -17%

% to revenues 16.0% 20.6%

Q FY



Q2 FY15 PRESS MEET

12

Key Balance Sheet Items₹ Cr

Particulars Sep’14 June’14

Cash, cash equivalents & other investments 2,874 3,295

Trade & other receivables 3,772 3,611

Inventories 2,812 2,532

Property, plant & equipment 4,656 4,535

Loans & borrowings (current & non current) 3,885 4,182

Trade & other payables 1,284 1,064

Equity 9,900 9,673

Q FY PRESS MEET

Q FY PRESS MEET



Q2 FY15 PRESS MEET

THANK YOU

Q2 FY15 PRESS MEET

13

Pressmeet Presentation Q2FY15

Documents